Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
The traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their e...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2020
|
| _version_ | 1826295563777212416 |
|---|---|
| author | Blagden, S Billingham, L Brown, L Buckland, S Cooper, A Ellis, S Fisher, W Hughes, H Keatley, D Maignen, F Morozov, A Navaie, W Pearson, S Shaaban, A Wydenbach, K Kearns, P |
| author_facet | Blagden, S Billingham, L Brown, L Buckland, S Cooper, A Ellis, S Fisher, W Hughes, H Keatley, D Maignen, F Morozov, A Navaie, W Pearson, S Shaaban, A Wydenbach, K Kearns, P |
| author_sort | Blagden, S |
| collection | OXFORD |
| description | The traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret. The Experimental Cancer Medicine Centres (ECMC) network, funded by the National Institute for Health Research (NIHR), Cancer Research UK (CRUK) and the Health Boards of Wales, Northern Ireland and Scotland, formed a working group with relevant stakeholders from clinical trials units, the pharmaceutical industry, funding bodies, regulators and patients to identify the main challenges of CID trials. The working group generated ten consensus recommendations. These aim to improve the conduct, quality and acceptability of oncology CID trials in clinical research and, importantly, to expedite the process by which effective treatments can reach cancer patients.
|
| first_indexed | 2024-03-07T04:02:58Z |
| format | Journal article |
| id | oxford-uuid:c538a2b8-cce6-4708-97f4-29f1379003ac |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:02:58Z |
| publishDate | 2020 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:c538a2b8-cce6-4708-97f4-29f1379003ac2022-03-27T06:29:25ZEffective delivery of Complex Innovative Design (CID) cancer trials—A consensus statementJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c538a2b8-cce6-4708-97f4-29f1379003acEnglishSymplectic Elements at OxfordSpringer Nature2020Blagden, SBillingham, LBrown, LBuckland, SCooper, AEllis, SFisher, WHughes, HKeatley, DMaignen, FMorozov, ANavaie, WPearson, SShaaban, AWydenbach, KKearns, PThe traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret. The Experimental Cancer Medicine Centres (ECMC) network, funded by the National Institute for Health Research (NIHR), Cancer Research UK (CRUK) and the Health Boards of Wales, Northern Ireland and Scotland, formed a working group with relevant stakeholders from clinical trials units, the pharmaceutical industry, funding bodies, regulators and patients to identify the main challenges of CID trials. The working group generated ten consensus recommendations. These aim to improve the conduct, quality and acceptability of oncology CID trials in clinical research and, importantly, to expedite the process by which effective treatments can reach cancer patients. |
| spellingShingle | Blagden, S Billingham, L Brown, L Buckland, S Cooper, A Ellis, S Fisher, W Hughes, H Keatley, D Maignen, F Morozov, A Navaie, W Pearson, S Shaaban, A Wydenbach, K Kearns, P Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement |
| title | Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement |
| title_full | Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement |
| title_fullStr | Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement |
| title_full_unstemmed | Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement |
| title_short | Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement |
| title_sort | effective delivery of complex innovative design cid cancer trials a consensus statement |
| work_keys_str_mv | AT blagdens effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT billinghaml effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT brownl effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT bucklands effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT coopera effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT elliss effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT fisherw effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT hughesh effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT keatleyd effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT maignenf effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT morozova effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT navaiew effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT pearsons effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT shaabana effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT wydenbachk effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement AT kearnsp effectivedeliveryofcomplexinnovativedesigncidcancertrialsaconsensusstatement |